Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Revolution Medicines (RVMD) Net Income towards Common Stockholders: 2019-2025

Historic Net Income towards Common Stockholders for Revolution Medicines (RVMD) over the last 7 years, with Sep 2025 value amounting to -$305.2 million.

  • Revolution Medicines' Net Income towards Common Stockholders fell 95.28% to -$305.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$961.0 million, marking a year-over-year decrease of 69.47%. This contributed to the annual value of -$600.1 million for FY2024, which is 37.52% down from last year.
  • Revolution Medicines' Net Income towards Common Stockholders amounted to -$305.2 million in Q3 2025, which was down 23.17% from -$247.8 million recorded in Q2 2025.
  • In the past 5 years, Revolution Medicines' Net Income towards Common Stockholders ranged from a high of -$37.2 million in Q1 2021 and a low of -$305.2 million during Q3 2025.
  • In the last 3 years, Revolution Medicines' Net Income towards Common Stockholders had a median value of -$156.3 million in 2024 and averaged -$163.9 million.
  • Data for Revolution Medicines' Net Income towards Common Stockholders shows a maximum YoY crashed of 185.87% (in 2023) over the last 5 years.
  • Revolution Medicines' Net Income towards Common Stockholders (Quarterly) stood at -$52.7 million in 2021, then decreased by 7.27% to -$56.5 million in 2022, then slumped by 185.87% to -$161.5 million in 2023, then declined by 20.45% to -$194.6 million in 2024, then tumbled by 95.28% to -$305.2 million in 2025.
  • Its Net Income towards Common Stockholders stands at -$305.2 million for Q3 2025, versus -$247.8 million for Q2 2025 and -$213.4 million for Q1 2025.